

of diagnostic tests based on recombinant yellow jacket venom allergens. Nevertheless, rVes v 5 and rVes v 1 had missed 8% of subjects with established allergy. Testing for rVes v 2b added only a minor contribution to diagnostic sensitivity. Primarily, 3 allergens were recognized as responsible for *Vespula* venom allergy, beyond Ves v 5 and Ves v 1, also Ves v 2, which occurs in isoforms.¹ Recently, a novel 100-kDa glycosylated protein with homology to dipeptidyl peptidases with allergenic potential, namely, Ves v 3, was reported as a yellow jacket allergen.⁷ rVes v 3 showed IgE reactivity in approximately 50% of *Vespula* allergic subjects (in overall 54 tested)⁸ and might be useful to diagnose the few patients who are not identified with rVes v 5, 1, and 2.

Clinically, we cannot afford to miss a patient who is sensitive to insect venom; thus, the whole venom (that contains all the venom allergens as a single test) needs to be the first line of laboratory evaluation. However, the identification of the disease-causing insect venom in venom allergy is often difficult. In such cases, commercially available CAP-FEIA tests based on recombinant rVes v 5 and rVes v 1 allergens should be helpful for the serological dissection of *Vespula* venom allergy.

We thank Lucas Mach, Daniel Kolarich, and Friedrich Altmann, Department of Applied Genetics and Cell Biology, University of Natural Resources and Life Science, Vienna, Austria, for recombinant Ves v 2b.

Peter Korošec, PhD^a
Rudolf Valenta, MD^b
Irene Mittermann, PhD^b
Nina Čelesnik, BS^a
Mira Šilar, BS^a
Mihaela Zidarn, MD^a
Mitja Košnik, PhD, MD^a

From ^athe University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia, and ^bthe Department of Pathophysiology and Allergy Research, Division of Immunopathology, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria. E-mail: peter.korossec@klinik-golnik.si.

This study was supported in part by the Slovenian research agency (ARRS), Christian Doppler Research Association, and the Austrian Science Fund (FWF).

Disclosure of potential conflict of interest: R. Valenta has received research support from the Austrian Science Fund, CDG, Biomas, and Phadia. The rest of the authors declare that they have no relevant conflicts of interest.

REFERENCES

- Hoffman DR. Allergens in Hymenoptera venom, XXV: the amino acid sequences of antigen 5 molecules and the structural basis of antigenic cross-reactivity. *J Allergy Clin Immunol* 1993;92:707-16.
- King TP, Lu G, Gonzalez M, Qian N, Soldatova L. Yellow jacket venom allergens, hyaluronidase and phospholipase: sequence similarity and antigenic cross-reactivity with their hornet and wasp homologs and possible implications for clinical allergy. *J Allergy Clin Immunol* 1996;98:588-600.
- Korošec P, Valenta R, Mittermann I, Čelesnik N, Eržen R, Zidarn M, et al. Low sensitivity of commercially available rApi m 1 for diagnosis of honeybee venom allergy. *J Allergy Clin Immunol* 2011;128:671-3.
- Sturm GJ, Hemmer W, Hawranek T, Lang R, Ollert M, Spillner E, et al. Detection of IgE to recombinant Api m 1 and rVes v 5 is valuable but not sufficient to distinguish bee from wasp venom allergy. *J Allergy Clin Immunol* 2011;128:247-8.
- Mittermann I, Zidarn M, Šilar M, Markovic-Housley Z, Aberer W, Korošec P, et al. Recombinant allergen-based IgE testing to distinguish honeybee and wasp allergy. *J Allergy Clin Immunol* 2010;125:1300-7.
- Kolarich D, Loos A, Leonard R, Mach L, Marzban G, Hemmer W, et al. A proteomic study of the major allergens from yellow jacket venoms. *Proteomics* 2007;7:1615-23.
- Müller U, Johansen N, Petersen AB, Fromberg-Nielsen J, Haeblerli G. Hymenoptera venom allergy: analysis of double positivity to honey bee and *Vespula* venom by estimation of IgE antibodies to species-specific major allergens Api m 1 and Ves v 5. *Allergy* 2009;64:543-8.

- Blank S, Seismann H, Bockisch B, Braren I, Cifuentes L, McIntyre M, et al. Identification, recombinant expression, and characterization of the 100 kDa high molecular weight Hymenoptera venom allergens Api m 5 and Ves v 3. *J Immunol* 2010;184:5403-13.

Available online January 24, 2012.
doi:10.1016/j.jaci.2011.12.975

Specific allergen concentration of WHO and FDA reference preparations measured using a multiple allergen standard

To the Editor:

Allergen measurements require well-defined allergen standards. Allergists rely on these measurements for dosing patients on immunotherapy with the aim of achieving maintenance doses of 5 to 20 μ g of specific allergen that have been associated with clinical efficacy.¹ Allergists need to know that allergen measurements made by manufacturers are consistent and can reliably be used in clinical practice. Allergen measurements are widely used in the indoor air quality industry to assess exposure in homes, the workplace, schools, and commercial buildings. They are routinely used for assessing health risks associated with allergen exposure, for assessing the efficacy of allergen avoidance procedures, and for developing new allergen control products.²

Measurements of allergens by ELISA rely on standards of known allergen concentration, but few national or international allergen standards exist. The World Health Organization/International Union of Immunological Societies (WHO/IUIS) Allergen Standardization Committee initiated a program to develop purified allergen standards for calibration of *in vitro* measurements. This initiative was funded by the European Union to develop certified reference materials for allergenic products ("Development of Certified Reference Materials for Allergenic Products and Validation of Methods for their Quantification," acronym CREATE). The aims of CREATE were to develop international reference materials with verifiable allergen content.^{3,4}

Our goal was to apply the principles of allergen standardization developed in CREATE to other purified allergens. We developed a single "universal" allergen standard (UAS) for use in ELISA and in a fluorescent multiplex array for indoor allergens.⁵ Purified proteins are essential in multiplex systems to reduce nonspecific interactions. Eight purified allergens (Der p 1, Der f 1, Der p 2, Fel d 1, Can f 1, Rat n 1, Mus m 1, and Bla g 2) were combined in the UAS. The protein concentration of the purified allergens was determined by amino-acid analysis, in keeping with CREATE. A detailed validation of the UAS and comparison with previous ELISA standards will be published elsewhere.⁶ Here, we report the concentration of specific allergens in WHO/IUIS and US Food and Drug Administration (FDA) reference preparations using the single multiallergen standard.

Specific allergen concentrations of WHO/IUIS and FDA reference preparations were determined by using ELISA (Table I). The WHO/IUIS *Dermatophagoides pteronyssinus* standard 82/518 has been widely used as a standard for measurements of allergen exposure with a reported concentration of 12.5 μ g Der p 1 per ampoule.⁷ A value of 7.2 μ g Der p 1 per ampoule was obtained by using the UAS, which is similar to estimates of 5 μ g Der p 1 per ampoule reported previously.^{8,9} The WHO/IUIS dog hair standard has an assigned potency of 100,000 IU per ampoule and contained 20.4 μ g Can f 1 per ampoule as determined by using the UAS.

TABLE I. Allergen concentration of reference standards measured by ELISA using the UAS

	Units	Allergen	Concentration
WHO-IUIS standards*			
<i>Dermatophagoides pteronyssinus</i> 82/518	100,000 IU/ampoule	Der p 1	7.2 µg/ampoule
Dog hair 84/685	100,000 IU/ampoule	Can f 1	20.4 µg/ampoule†
FDA standards‡			
<i>D pteronyssinus</i> E8	10,000 AU/mL	Der p 1	20.3 µg/mL
<i>D pteronyssinus</i> E10	10,000 AU/mL	Der p 1	27.6 µg/mL
<i>D pteronyssinus</i> E8	10,000 AU/mL	Der p 2	23.4 µg/mL
<i>D pteronyssinus</i> E10	10,000 AU per mL	Der p 2	23.5 µg/mL
<i>D farinae</i> E9	10,000 AU/mL	Der f 1	19.9 µg/mL
<i>D farinae</i> E10	10,000 AU/mL	Der f 1	29.2 µg/mL
<i>D farinae</i> E9	10,000 AU/mL	Der f 2§	19.2 µg/mL
<i>D farinae</i> E10	10,000 AU/mL	Der f 2§	15.0 µg/mL
Cat hair E4	10,000 BAU/mL or 7.0 Fel d 1 units/mL	Fel d 1	5.4 µg/mL
Cat pelt E4	10,000 BAU/mL or 14.8 Fel d 1 units/mL	Fel d 1	15.6 µg/mL
Cat hair E5	10,000 BAU/mL or 22.0 Fel d 1 units per mL	Fel d 1	24.8 µg/mL

BAU, Bioequivalent allergy unit.

*Mean of duplicate determinations.

†Based on these data, 1 IU Can f 1 = ~5 ng Can f 1.

‡Mean data from measurements by 2 operators on 3 separate occasions. The values for Fel d 1 units in the cat hair and pelt standards were determined by radial immunodiffusion by the FDA (data kindly provided by Cherry Valerio, FDA Center for Biologics Evaluation and Research).

§Determined using a separate in-house natural Der f 2 standard with a concentration of 1.25 mg/mL by amino acid analysis.

|| 1 FDA unit Fel d 1 = ~1 µg Fel d 1.

There are no published reports of the specific allergen concentrations of US FDA reference materials. The 10,000 allergy units/mL *D pteronyssinus* references had similar concentrations of Der p 1 and Der p 2 in both the E8 and E10 standards (range, 20.3–27.6 µg/mL) (Table I). The 10,000 allergy units/mL *D farinae* references (E9 and E10) contained comparable levels of Der f 1 to the levels of Der p 1 seen in the *D pteronyssinus* references. It was not possible to use the Der p 2 standard in the UAS for the calibration of Der f 2 in *D farinae* references. The Der p 2 standard in the UAS underestimated the amount of Der f 2 by ~8-fold (data not shown). The Der f 2 concentration of 10,000 allergy units/mL *D farinae* references was determined by using a purified in-house Der f 2 standard (Table I). The Der f 2 concentrations of the E9 and E10 *D farinae* references were very similar. It was reassuring that the allergen levels in E8 and E9 (previous mite standards) were broadly similar to those of the current E10 standard. Overall, Group 1 and Group 2 allergen levels were comparable, and in some cases almost identical, in the FDA references for both mite species.

The FDA assigns potency to cat allergenic products based on the Fel d 1 content determined by radial immunodiffusion. Allergenic products containing 10 to 19.9 FDA units/mL of Fel d 1 have an assigned potency of 10,000 bioequivalent allergy units/mL.¹⁰ The Fel d 1 values in units of 2 of the FDA references (E4 and E5 hair) were outside of the recommended range. The Fel d 1 concentrations in micrograms per milliliter of the FDA cat references (E4 and E5) determined by ELISA using the UAS were consistent with the results obtained by radial immunodiffusion (Table I).

Our data confirm that the Der p 1 level of 12.5 µg per ampoule assigned to the WHO/IUIS *D pteronyssinus* standard (National Institute for Biological Standards and Control 82/518) is an overestimate and that the actual value is in the range of 5 to 7 µg per ampoule.^{8,9} The data show that 1 unit Can f 1 in the WHO/IUIS dog hair extract (National Institute for Biological Standards and Control 84/685) corresponds to 5 ng Can f 1 and that 1 FDA unit Fel d 1 is ~1 µg Fel d 1. Values obtained by using previous

standards have been applied to many studies involving thresholds or guidelines for exposure levels that result in allergic sensitization or symptom exacerbations.⁶ At this point, we do not believe that revision of such guidelines in the absence of further epidemiologic data would be worthwhile. Rather, future studies should incorporate purified allergen standards into the exposure assessment to generate a body of data based on standards that fulfill the CREATE principles.

Dosing of immunotherapy based on measurements of specific allergens plays an increasing role in allergy practice.¹ Although several US allergen manufacturers routinely measure specific allergens in their immunotherapy products, these measurements are not based on a national standard and may not be directly comparable. Our data provide the specific allergen concentrations in mite and cat allergen reference preparations used by the FDA for potency testing of all US standardized allergenic products. This provides a mechanism for standardizing allergen measurements in US products that allergists use for immunotherapy.

The results suggest that the approach of using multiallergen standards could be extended to other sources, for example, pollens, molds, and foods, where purified allergens are available. It is critically important that regulatory agencies generate purified natural or recombinant allergen standards that researchers and companies can use as reference preparations. Two of the allergens used in CREATE, Bet v 1 and Phl p 5, are being formulated as biological reference preparations by the European Directorate for the Quality of Medicines.⁴ ELISA tests for each allergen are also being validated to produce certified ELISA products that can be used for analytical purposes. Once completed, the biological reference preparations will be incorporated into the European Pharmacopoeia and will become international standards for licensing of allergenic products. Our data demonstrate the feasibility of applying CREATE principles to other allergens and underline the need for validated purified allergens and assays to be developed and maintained by standardization agencies and regulatory authorities.

We are grateful to the National Institute for Biological Standards and Control (Potters Bar, United Kingdom) and to the US Food and Drug Administration, Center for Biologics Evaluation and Research (Rockville, Md), for providing allergen reference materials.

Stephanie Filep, BS^a
Amy Tsay, MSc^a
Lisa D. Vailes, MS^a
Gabriele Gadermaier, PhD^b
Fatima Ferreira, PhD^b
Elizabeth Matsui, MD, MPH^c
Eva M. King, PhD^a
Martin D. Chapman, PhD^a

From ^aIndoor Biotechnologies, Inc, Charlottesville, Va; ^bthe Department of Molecular Biology, Christian Doppler Laboratory for Allergy Diagnosis and Therapy, University of Salzburg, Salzburg, Austria; and ^cthe Department of Pediatric Allergy and Immunology, Johns Hopkins Hospital, Baltimore, Md. E-mail: mdc@inbio.com.

S.F., A.T., L.D.V., E.M.K., and M.D.C. were supported by Indoor Biotechnologies, Inc, and by National Institutes of Health Small Business Innovation and Research (SBIR) Award ES55545C from the National Institute of Environmental Health Sciences. L.D.V., M.D.C., G.G., and F.F. were supported by the European 5th Framework Programme CREATE project (G6RD-CT-2001-00582). E.M. was supported by the National Institutes of Health (National Institute of Allergy and Infectious Diseases grants R01AI070630 and R01AI081845; National Institute of Environmental Health Sciences grants P50ES015903 and P01ES018176) and by the Environmental Protection Agency.

Disclosure of potential conflict of interest: S. Filep, L. D. Vailes, and E. M. King are employees of Indoor Biotechnologies, Inc. A. Tsay has received research support from the National Institute of Environmental Health Sciences (NIEHS) and is currently employed by Rho Inc, Chapel Hill, NC. F. Ferreira has consulted for AllergenOnline and Biomay AG, is on the Scientific Advisory Board of Indoor Biotechnologies Inc, and has received research support from the Christian Doppler Research Association, the Austrian Science Fund, and the European Union. E. Matsui has received research support from the National Institutes of Health. M. D. Chapman is president and CEO of Indoor Biotechnologies and has received research support from NIEHS and the National Institute of Allergy and Infectious Diseases. G. Gadermaier declares that she has no relevant conflicts of interest.

REFERENCES

- Nelson HS. Allergen immunotherapy: where is it now? *J Allergy Clin Immunol* 2007;119:769-79.
- Platts-Mills TA, Vervloet D, Thomas WR, Aalberse RC, Chapman MD. Indoor allergens and asthma: report of the Third International Workshop. *J Allergy Clin Immunol* 1997;100:S2-24.
- van RR, Chapman MD, Ferreira F, Vieths S, Bryan D, Cromwell O, et al. The CREATE project: development of certified reference materials for allergenic products and validation of methods for their quantification. *Allergy* 2008;63:310-26.
- Chapman MD, Ferreira F, Villalba M, Cromwell O, Bryan D, Becker WM, et al. The European Union CREATE project: a model for international standardization of allergy diagnostics and vaccines. *J Allergy Clin Immunol* 2008;122:882-9.
- Earle CD, King EM, Tsay A, Pittman K, Saric B, Vailes L, et al. High-throughput fluorescent multiplex array for indoor allergen exposure assessment. *J Allergy Clin Immunol* 2007;119:428-33.
- Filep S, Tsay A, Vailes LD, Gadermaier G, Ferreira F, Matsui EC, et al. A multi-allergen standard for immunoassays: CREATE principles applied to eight purified allergens. *Allergy* 2011 Nov 18. doi: 10.1111/j.1398-9995.2011.02750.x. [Epub ahead of print].
- Ford AW, Rawle FC, Lind P, Spieksma FT, Lowenstein H, Platts-Mills TA. Standardization of *Dermatophagoides pteronyssinus*: assessment of potency and allergen content in ten coded extracts. *Int Arch Allergy Appl Immunol* 1985;76:58-67.
- Yasueda H, Saito A, Akiyama K, Maeda Y, Shida T, Sakaguchi M, et al. Estimation of Der p and Der f I quantities in the reference preparations of *Dermatophagoides* mite extracts. *Clin Exp Allergy* 1994;24:1030-5.
- Meyer CH, Bond JF, Chen MS, Kasaian MT. Comparison of the levels of the major allergens Der p I and Der p II in standardized extracts of the house dust mite, *Dermatophagoides pteronyssinus*. *Clin Exp Allergy* 1994;24:1041-8.
- Turkeltaub PC. Biological standardization. *Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M* 1997;91:145-56.

Available online January 24, 2012.
doi:10.1016/j.jaci.2011.12.978

Increased serum CRH levels with decreased skin CRHR-1 gene expression in psoriasis and atopic dermatitis

To the Editor:

Autoimmune skin diseases, such as psoriasis and atopic dermatitis (AD), are chronic inflammatory skin disorders mediated primarily by T cells,¹ but mast cells are also implicated.² Symptoms of both psoriasis and AD worsen with stress.³ Acute stress leads to increased vascular permeability and inflammation of skin, through mast-cell activation by corticotropin-releasing hormone (CRH) both in rodents⁴ and in humans.⁵ CRH and CRH receptor 1 (CRHR-1) are both expressed in human skin,⁶ leading to the hypothesis that CRH may be involved in the pathophysiology of skin diseases.⁷

Full-length 3-mm³ punch skin biopsies were collected for diagnostic purposes from subjects with psoriasis and AD who had not received any medication for 15 days prior to biopsy and were free from any systemic allergic or inflammatory disease. Serum was also collected from patients and controls. The Medical Ethics Committee approved this protocol. The Psoriasis Area and Severity Index (PASI) score was recorded for some of the patients with psoriasis; no severity index score was obtained from the patients with AD. Also, some patients with psoriasis and AD filled the State-Trait Anxiety Inventory (STAI), which has been validated for the Greek population,⁸ to investigate the extent of stress. The STAI measures separate constructs of psychosocial stress and clearly differentiates the temporary condition of "state anxiety" (STATE now) from the more general and long-standing quality of "trait anxiety" (STATE trait).

Serum level and skin gene expression results from patients were compared with those of controls by using the Mann-Whitney nonparametric *U* test. There was no statistical difference in the mean age between controls and patients. All subject characteristics and the summary of the results are presented in Table I.

For CRH serum measurements, the mean age for patients with psoriasis (n = 48; 23 women and 25 men, 27 of whom had a PASI score of 10-50) was 46 ± 17 years, while the mean age for controls (n = 19; 10 women and 9 men) was 47 ± 16 years. Serum CRH levels were higher (*P* = .0001) in patients with psoriasis (22.5 ± 13.7 pg/mL) than in controls (9.7 ± 4.2 pg/mL) (Fig 1, A). When patients with psoriasis were separated into those with PASI scores of less than 10 and those with PASI scores of more than 10, there was a statistically significant increase (*P* = .0001) in patients with psoriasis with PASI scores of more than 10 (Fig 1, A) but not in those with PASI scores of less than 10 (data not shown). For CRH serum measurements, the mean age for patients with AD (n = 15; 9 women and 6 men) was 36 ± 18 years, while the mean age for controls (n = 19; 10 women and 9 men) was 47 ± 16 years. Serum CRH levels were higher (*P* = .0001) in patients with AD (31.0 ± 19.5 pg/mL) than in controls (9.7 ± 4.2 pg/mL) (Fig 1, A).

For cytokine serum measurements, the mean age for patients with psoriasis (n = 56; 26 women and 30 men, 31 of whom had PASI scores of 10-50) was 40 ± 14 years, while the mean age for controls (n = 33; 14 women and 19 men) was 48 ± 18 years. Serum cytokines and vascular endothelial growth factor (VEGF) were evaluated by using Milliplex microbead technology, and the measurements were performed by Millipore (St Charles, Mich). Serum levels of IL-6, IL-9, IL-33, TNFβ, and thymic stromal